Medartis H1 FY26 core net profit turns to CHF 6.8 million; net sales rise 30.7% to CHF 160.8 million

(AWP Alliance News) - Medartis reported H1 2026 net sales of CHF 160.8 million, up 30.7%, while IFRS net profit swung to CHF 4.9 million from a loss a year earlier. IFRS EBITDA rose to CHF 27.6 million from CHF 21 million, lifting the EBITDA margin to 17.2% from 17%.

On a core basis, EBITDA climbed to CHF 28.8 million from CHF 21.8 million, pushing the core EBITDA margin up 0.2 percentage points to 18%. CEO Matthias Schupp said the US rollout of the TOUCH thumb prosthesis is running ahead of plan, prompting Medartis to raise its 2026 unit projection to 1,800 from 1,200. Guidance for 2026 was raised to organic core sales growth of 17%-19% from 16%-18%, with a core EBITDA margin in the high teens.

https://www.publicnow.com/view/085B993C480CC502958953400CEC2036CE40D85F…

Disclaimer: This news brief was created using generative artificial intelligence. Medartis Holding AG published the original content used to generate this news brief via EQS News on August 18, 2026, and is solely responsible for the information contained therein.